Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving TolvaptanKiyotaka Uchiyama, Kaori Hayashi, Takashin Nakayama et al.|Kidney International Reports|2025Cited by 16
Impact of home-based exercise on residual kidney function in patients initiating peritoneal dialysis: A feasibility multicenter randomized controlled trialKiyotaka Uchiyama, Naoki Washida, Seiki Yamada et al.|Peritoneal Dialysis International|2024Cited by 4
Prognosis and characteristics of Corynebacterium exit site infection: a single-center retrospective studyKazuya Sugita, Kiyotaka Uchiyama, Naoki Washida et al.|Renal Replacement Therapy|2024Cited by 0
Erratum to “Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan” [Kidney International Reports Volume 10, Issue 4, April 2025, Pages 1063-1075]Kiyotaka Uchiyama, Kaori Hayashi, Daisuke Kamano et al.|Kidney International Reports|2025Cited by 0